Back

Kidney disease reprograms microbiome-host signaling to promote heart failure

Yarritu, A.; Anders, W.; Thiele, A.; Potapenko, O.; Schumacher, F.; Szijarto, I. A.; Matz-Rauch, A.; Versnjak, J.; Gebremedhin, N.; McParland, V.; Heckscher, S.; Kamboj, S.; Trimarchi, G.; Anandakumar, H.; Fuckert, F.; Hoffmann, C.; Hassan, S. A.; Bonnekoh, P. M.; Wimmer, M. I.; Behrens, F.; Voelkl, J.; Kramann, R.; Kintscher, U.; Kuehne, T.; Kleuser, B.; Zernecke, A.; Oefner, P. J.; Gronwald, W.; Dettmer, K.; Eckardt, K.-U.; Mueller, D. N.; Kelm, M.; Holle, J.; Bartolomaeus, H.; Wilck, N.

2026-01-12 immunology
10.64898/2026.01.10.698142 bioRxiv
Show abstract

Gut microbiome-derived metabolites regulate host physiology, with systemic levels controlled by renal excretion. In kidney disease, impaired clearance leads to metabolite accumulation, inflammation, and secondary cardiovascular damage. We show that adverse cardiac remodeling following kidney disease critically depends on the microbiome. We identify microbiome-derived indoxyl sulfate-mediated activation of the aryl hydrocarbon receptor (AhR) as a key mechanism inducing IL-17A-producing T cells, thereby promoting cardiac fibrosis. AhR inhibition attenuates inflammation and cardiac remodeling. On population level, IL-17A is elevated in chronic kidney disease, particularly with coexisting heart failure. Mechanistically, AhR and IL-17A signaling induce a conserved pro-fibrotic phenotype in both murine and human cardiac fibroblasts. This work identifies a microbiome-AhR-IL-17A axis as a mediator and druggable target of cardiovascular damage in kidney disease.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.